Motley Fool released their latest disclosures for their biotech and pharma positions. The firm and its writers are currently holding and recommending Bristol Myers Squibb, Pfizer, and Vertex. They are also holding Moderna and Regeneron, while recommending J&J and the SPDR S&P Biotech ETF.